特発性肺線維症の市場：薬剤タイプ、流通チャネル、エンドユーザー別-2025-2030年の世界予測

特発性肺線維症市場は、2023年に34億6,000万米ドルと評価され、2024年には36億5,000万米ドルに達すると予測され、CAGR 5.47％で成長し、2030年には50億3,000万米ドルになると予測されています。

特発性肺線維症（IPF）は、原因不明の肺組織の瘢痕化を特徴とする進行性の慢性肺疾患であり、深刻な呼吸器疾患につながります。市場調査範囲では、IPFは主に世界の高齢化社会における罹患率の増加によって定義され、効果的な治療オプションと患者管理ソリューションの必要性が高まっています。IPFに対処する必要性は、決定的な治癒療法がないことによって強調されており、医薬品開発と治療法の強化に注力することが不可欠です。最終用途は、主に製薬会社、ヘルスケアプロバイダー、革新的な創薬、先進的な診断ツール、包括的なケア戦略に注力する研究機関です。IPF市場に影響を与える主な成長要因としては、ゲノムおよびバイオテクノロジーの進歩、資金援助や有利な政策による政府支援、早期診断と治療を提唱する啓発活動の増加などが挙げられます。最新の潜在的ビジネスチャンスは個別化医療と生物製剤にあり、個人の遺伝的・分子的プロファイルに対応することでIPF治療に革命をもたらすことが期待されています。企業は、最先端の共同研究に投資し、人工知能を活用して創薬と開発を加速させることが推奨されます。このような機会にもかかわらず、高い治療費、厳しい規制要件、製剤化を複雑にするIPFの複雑な性質などの課題も残っています。さらに、病態の理解が限られていることも大きな障害となっています。市場関係者は、遺伝子編集技術、リキッドバイオプシーのような診断手法の改善、患者中心のケアモデルといった革新的な分野に注力し、事業成長を目指すべきです。市場の性質に関する考察では、製品パイプラインを強化するための継続的な研究開発と戦略的提携によって、競合情勢が促進されていることが示唆されています。全人的な治療ソリューションを重視し、包括的な患者支援サービスを育成することは、市場を効果的にナビゲートし、競争上の優位性と患者の福祉の両方を確保するための重要な戦略です。

市場力学：急速に進化する特発性肺線維症市場の主要市場インサイトを公開

特発性肺線維症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 特発性肺線維症の普及率上昇
  • 医療・診断技術の進歩
• 市場抑制要因
  • 治療・処置にかかるコストの高さ
• 市場機会
  • 精密医療の革新と標的療法の開発
  • 特発性肺線維症の希少疾病指定とIPF治療薬開発へのインセンティブ
• 市場の課題
  • IPF治療における副作用や潜在的リスクに関する治療上の懸念

ポーターの5つの力：特発性肺線維症市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：特発性肺線維症市場における外部からの影響の把握

外部マクロ環境要因は、特発性肺線維症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析特発性肺線維症市場における競合情勢の把握

特発性肺線維症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス特発性肺線維症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、特発性肺線維症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨特発性肺線維症市場における成功への道筋を描く

特発性肺線維症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 特発性肺線維症の普及率の上昇
    • 医療および診断技術の進歩
  • 抑制要因
    • 治療費の高騰
  • 機会
    • 精密医療におけるイノベーションと標的治療の開発
    • 特発性肺線維症の希少疾病指定とIPF治療薬開発へのインセンティブ
  • 課題
    • IPF治療の副作用と潜在的リスクに関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 特発性肺線維症の市場薬の種類別

• ニンテダニブ
• ピルフェニドン

第7章 特発性肺線維症の市場：流通チャネル別

• オフライン
• オンライン

第8章 特発性肺線維症の市場：エンドユーザー別

• 外来手術センター
• 在宅介護施設
• 病院・クリニック

第9章 南北アメリカの特発性肺線維症の市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の特発性肺線維症の市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの特発性肺線維症の市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Algernon Pharmaceuticals Inc.
• Alkem Laboratories Ltd.
• AstraZeneca PLC
• Avalyn Pharma Inc.
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb
• Camber Pharmaceuticals, Inc. by Hetero Labs Limited
• Chemo Healthcare Pvt. Ltd.
• Cipla Limited
• Dr Reddy's Laboratories Ltd.
• FibroGen, Inc.
• Galapagos NV
• Glenmark Pharmaceuticals Ltd.
• GNI Group Ltd.
• Horizon Therapeutics PLC by Amgen Inc.
• Lupin Ltd.
• MediciNova, Inc.
• Merck & Co.
• Mission Therapeutics
• MSN Laboratories Private Limited
• Sandoz International GmbH
• Sanify Healthcare Private Limited
• Shionogi & Co., Ltd.
• Teva Pharmaceuticals, Inc.

LIST OF FIGURES

• FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET RESEARCH PROCESS
• FIGURE 2. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET DYNAMICS
• TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

The Idiopathic Pulmonary Fibrosis Market was valued at USD 3.46 billion in 2023, expected to reach USD 3.65 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 5.03 billion by 2030.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and chronic lung condition characterized by unexplained scarring of lung tissue, leading to severe respiratory issues. In the scope of market research, IPF is defined primarily by its growing incidence rate among the global aging population, thus prompting an increased necessity for effective treatment options and patient management solutions. The necessity for addressing IPF is underscored by the lack of definitive curative therapies, making it imperative to focus on drug development and therapy enhancement. Application and end-use scope principally encompass pharmaceutical companies, healthcare providers, and research institutions focusing on innovative drug discovery, advanced diagnostic tools, and comprehensive care strategies. Key growth factors influencing the IPF market include advancements in genomics and biotechnology, governmental support through funding and favorable policies, and increasing awareness initiatives advocating for early diagnosis and treatment. The latest potential opportunities lie in personalized medicine and biologics, which promise to revolutionize IPF treatment by catering to individual genetic and molecular profiles. Companies are recommended to invest in cutting-edge research collaborations and leverage artificial intelligence for accelerated drug discovery and development. Despite these opportunities, challenges persist such as high treatment costs, stringent regulatory requirements, and the complex nature of IPF which complicates drug formulation. Moreover, the limited understanding of the disease pathogenesis poses significant hurdles. Market players should focus on areas of innovation such as gene editing technologies, improved diagnostic methodologies like liquid biopsy, and patient-centric care models for business growth. Insights into the market's nature suggest a competitive landscape, driven by continuous R&D and strategic partnerships to enhance product pipelines. Emphasizing holistic treatment solutions and fostering comprehensive patient support services will be crucial strategies to navigate the market effectively, ensuring both competitive advantage and patient welfare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Idiopathic Pulmonary Fibrosis Market

The Idiopathic Pulmonary Fibrosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of idiopathic pulmonary fibrosis
  • Advancements in the medical and diagnostic technology
• Market Restraints
  • High cost of therapies and treatments
• Market Opportunities
  • Innovations in the precision medicine and development of targeted therapies
  • Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
• Market Challenges
  • Concerns associated with side-effects and potential risk of IPF treatment

Porter's Five Forces: A Strategic Tool for Navigating the Idiopathic Pulmonary Fibrosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Idiopathic Pulmonary Fibrosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Idiopathic Pulmonary Fibrosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Idiopathic Pulmonary Fibrosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Idiopathic Pulmonary Fibrosis Market

A detailed market share analysis in the Idiopathic Pulmonary Fibrosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Idiopathic Pulmonary Fibrosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Idiopathic Pulmonary Fibrosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Idiopathic Pulmonary Fibrosis Market

A strategic analysis of the Idiopathic Pulmonary Fibrosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Idiopathic Pulmonary Fibrosis Market, highlighting leading vendors and their innovative profiles. These include Algernon Pharmaceuticals Inc., Alkem Laboratories Ltd., AstraZeneca PLC, Avalyn Pharma Inc., Biogen, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Camber Pharmaceuticals, Inc. by Hetero Labs Limited, Chemo Healthcare Pvt. Ltd., Cipla Limited, Dr Reddy's Laboratories Ltd., FibroGen, Inc., Galapagos NV, Glenmark Pharmaceuticals Ltd., GNI Group Ltd., Horizon Therapeutics PLC by Amgen Inc., Lupin Ltd., MediciNova, Inc., Merck & Co., Mission Therapeutics, MSN Laboratories Private Limited, Sandoz International GmbH, Sanify Healthcare Private Limited, Shionogi & Co., Ltd., and Teva Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Idiopathic Pulmonary Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Nintedanib and Pirfenidone.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Home Care Facilities, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of idiopathic pulmonary fibrosis
    • 5.1.1.2. Advancements in the medical and diagnostic technology
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapies and treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovations in the precision medicine and development of targeted therapies
    • 5.1.3.2. Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with side-effects and potential risk of IPF treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Idiopathic Pulmonary Fibrosis Market, by Drug Type

• 6.1. Introduction
• 6.2. Nintedanib
• 6.3. Pirfenidone

7. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Offline
• 7.3. Online

8. Idiopathic Pulmonary Fibrosis Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Home Care Facilities
• 8.4. Hospitals & Clinics

9. Americas Idiopathic Pulmonary Fibrosis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Idiopathic Pulmonary Fibrosis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Algernon Pharmaceuticals Inc.
• 2. Alkem Laboratories Ltd.
• 3. AstraZeneca PLC
• 4. Avalyn Pharma Inc.
• 5. Biogen, Inc.
• 6. Boehringer Ingelheim International GmbH
• 7. Bristol Myers Squibb
• 8. Camber Pharmaceuticals, Inc. by Hetero Labs Limited
• 9. Chemo Healthcare Pvt. Ltd.
• 10. Cipla Limited
• 11. Dr Reddy's Laboratories Ltd.
• 12. FibroGen, Inc.
• 13. Galapagos NV
• 14. Glenmark Pharmaceuticals Ltd.
• 15. GNI Group Ltd.
• 16. Horizon Therapeutics PLC by Amgen Inc.
• 17. Lupin Ltd.
• 18. MediciNova, Inc.
• 19. Merck & Co.
• 20. Mission Therapeutics
• 21. MSN Laboratories Private Limited
• 22. Sandoz International GmbH
• 23. Sanify Healthcare Private Limited
• 24. Shionogi & Co., Ltd.
• 25. Teva Pharmaceuticals, Inc.